The chapter explores how PCSK9 genetic variants can influence LDL levels and the risk of type 2 diabetes, shedding light on adverse metabolic consequences. It discusses the implications of HMG-CoA reductase polymorphisms on diabetes risk and the potential consequences of lipid-lowering interventions. The conversation underscores the importance of considering various health factors like all-cause mortality, cancer risks, infections, and drug effects when assessing the effects of lowering cholesterol levels on overall health outcomes.
Today, Paul and Mike unpack their opinions about lipids. They talk about true risk for cardiovascular disease, primary versus secondary prevention, lipid lowering drugs, and share their thoughts on a recent podcast episode with Peter Attia.
*Produced by Mountain Valley Media
00:06:08 Blood markers & imaging techniques of metabolic function
00:14:38 Gene mutations
00:20:28 LDL & Plaque burden
00:27:23 Money in statins
00:31:38 Downsides of lowering LDL
01:21:23 The downsides of popular cholesterol lowering drugs
01:41:07 Should we fear heart attacks?
01:45:23 PCSK9 Inhibitors
01:52:43 Risk profile of Statins
01:53:02 Risk vs. reward of Ezetimibe
02:04:02 Primary vs. secondary prevention
Resources:
Debunking Sugar Claims: What Dr. Lustig Got Wrong On The Huberman Podcast:
https://www.youtube.com/watch?v=JcEmSgbMfco&t=2933s
Work With Mike: https://mikefave.com/